Pangaea Rx Antiviral Description
Dosage: Sublingual as necessary. Note: Each droplet measures .05mL; 20 droplets equal 1mL tincture
volume.
Active Ingredients: Pharmaceutical-grade, hemp-derived CBDa & CBGa Organic terpenes: Limonene,
Myrcene, Alpha Pinene, Beta Caryophyllene, Humulene, and Linalool
Inactive Ingredients: Organic
Coconut Oil (MCT)
Contaminant Analysis:
Heavy Metals: Not Detected (ND)
Lead: ND
Arsenic: ND
Residual Solvents: ND
Does not contain THC, metals, solvents, pesticides,
or GMOs
Microbial Analysis:
Total Aerobic count < 2,000 cfu/g
Total yeast and mold < 200 cfu/g
E.Coli = Negative
Salmonella = Negative
Attributes:
Pharmaceutical-grade, hemp-derived CBDa & CBGa
Total 1000mg cannabinoid potency
ZERO THC
Proprietary, AntiViral organic terpene profile
GMP Manufactured
Non-GMO
Building on the research from Oregon State University1 that revealed the virus-disrupting and inhibiting
properties of CBDa and CBGa, we developed our AntiViral Formula. PangaeaRx AntiViral Formula is a
complete, plant-based therapeutic driven by our AntiViral terpene profile and compounded with a total
of 1000mg’s of pharmaceutical-grade CBDa and CBGa. Together, our AntiViral profile adds multi-level
engagement with layers of anti-bacterial and immunity-building properties to further combat viral
infections and increase overall efficacy. The AntiViral terpene profile is a proprietary profile consisting
of Limonene, Myrcene, Alpha Pinene, Beta-Caryophyllene, Humulene, and Linalool which is
characterized by an earthy orange flavor with a slight spicey finish. A market-leading therapeutic,
PangaeaRx AntiViral Formula is the ideal therapeutic to include in your immunization strategy.
Packaging:
Colored 30mL glass bottle maintains product integrity
Full batch accountability and traceability
Shelf Life: 18 months
Store in a cool, dark and dry environment
These statements have not been evaluated by the FDA. This product is not intended to diagnose,
treat, cure, or prevent any disease.
1 Van Breemen, Richard B. and Muchiri, Ruth N. and Bates, Timothy A. and Weinstein, Jules B. and Leier,
Hans C. and Farley, Scotland and Tafesse, Fikadu G. “Cannabinoids Block Cellular Entry of SARS-CoV-2
and the Emerging Variants”. ACS Publications. 10 January 2022.
https://pubs.acs.org/doi/10.1021/acs.jnatprod.1c00946
